Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIP vs VeIP in Relapsed/Resistant Germ Cell Tumors
NCT00072215Phase 3Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2004
- Primary completion
- Apr 2005
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection in germ cell tumor (GCT) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 2 months. Started Apr 2004; status: terminated.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00072215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072215.